You are here: Industry Insights > Trovagene

News List

Trovagene Announces Data Showing Ability of Onvansertib to Rescue Venetoclax-Resistance in AML americanpharmaceuticalreview
December 11, 2019
Trovagene announced new in-vitro and in-vivo data suggesting that onvansertib may provide a new therapeutic option for patients who develop resistance to frontline treatment with venetoclax.
Trovagene Initiates Enrollment for KRAS-Mutated Colorectal Cancer Trial americanpharmaceuticalreview
July 10, 2019
Trovagene announced the initiation of patient enrollment of its Phase 1b/2 study of onvansertib in combination with FOLFIRI and Avastin® (bevacizumab) for second-line treatment of patients with metastatic colorectal cancer (mCRC) with a KRAS mutation (NCT
Trovagene Announces Collaboration with Nektar to Evaluate Onvansertib, ONZEALD™ americanpharmaceuticalreview
May 24, 2019
Trovagene and Nektar have entered into a research collaboration to explore the combination of Trovagene's PLK1 inhibitor, onvansertib, and Nektar's topoisomerase I inhibitor, ONZEALD ...
Trovagene Announces Patent for Combination of Onvansertib with Anti-Androgen Drugs americanpharmaceuticalreview
January 24, 2019
Trovagene announced the issuance of a new patent (10,155,006), entitled Combination Therapies and Methods of Use Thereof for Treating Cancer....
Trovagene Receives USAN Approval for Onvansertib americanpharmaceuticalreview
August 16, 2018
Trovagene announced the United States Adopted Name (USAN) Council has approved Onvansertib as the nonproprietary (generic) name for its drug candidate.....
Trovagene Announces Activation of First Clinical Trial Site in AML Trial americanpharmaceuticacreview
November 14, 2017
Trovagene announced the activation of its clinical trial site for its Phase 1b/2 multicenter trial of PCM-075 in patients with AML, with Virginia Cancer Specialists and Principal Investigator, Dr. Alexander Spira.
PCM-075 Demonstrates Synergy with HDAC Inhibitor in Non-Hodgkin Lymphoma Cell Lines americanpharmaceuticalreview
August 22, 2017
Trovagene announced compelling results of preclinical research of PCM-075 with a Histone deacetylase (HDAC) inhibitor in Non-Hodgkin Lymphoma (NHL) cell lines.
PLK1 Inhibitor PCM-075 Enhances Efficacy of a FLT3 inhibitor in Combination Therapy americanpharmaceuticalreview
August 17, 2017
Trovagene announced positive data from a preclinical in-vivo study examining the combination of their PLK1 inhibitor, PCM-075, with a leading investigational FLT3 Inhibitor.
Trovagene announces agreement with Novogene biospectrumasia
July 14, 2017
Through this agreement, Novogene will purchase NextCollect, Trovagene's proprietary urine collection and nucleic acid preservation device for validation in the Chinese market.
Trovagene Submits Investigational NDA to Initiate Phase 1b/2 PCM-075 Clinical Trial for AML pharmaceutical-technology
June 28, 2017
Trovagene announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to conduct a Phase 1b/2 clinical trial of PCM-075, their polo-like kinase 1 (PLK1) inhibitor for the treatment of patients w